Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients
- PMID: 8097114
- DOI: 10.1016/0006-3223(93)90288-o
Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients
Abstract
The relationship between central D2-dopamine receptor occupancy and antipsychotic drug effects was examined in a double-blind study. Raclopride was the compound used to induce a selective occupancy of the D2-dopamine receptors. In addition, 11C-labeled raclopride was the radioligand used to measure occupancy by positron emission tomography (PET). Seventeen schizophrenic patients were randomly assigned to one of three parallel groups treated for 4 weeks with daily doses of 2, 6, or 12 mg of raclopride. D2-receptor occupancy was determined by PET at steady-state conditions in 13 patients who completed the study. A statistically significant relationship was demonstrated between antipsychotic effect and degree of D2-receptor occupancy (p < 0.05). Patients with extrapyramidal side effects had significantly higher D2-receptor occupancy than those without (p = 0.02). The finding of a relationship between selective occupancy of the D2-dopamine receptors and clinical effects in schizophrenic patients principally provides new support for the dopamine hypothesis of antipsychotic drug action.
Similar articles
-
Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients.J Clin Psychopharmacol. 1998 Aug;18(4):305-10. doi: 10.1097/00004714-199808000-00010. J Clin Psychopharmacol. 1998. PMID: 9690696
-
Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.Am J Psychiatry. 1999 Jun;156(6):869-75. doi: 10.1176/ajp.156.6.869. Am J Psychiatry. 1999. PMID: 10360125 Clinical Trial.
-
Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.Neuropsychopharmacology. 2007 Jun;32(6):1209-15. doi: 10.1038/sj.npp.1301242. Epub 2006 Nov 1. Neuropsychopharmacology. 2007. PMID: 17077809 Clinical Trial.
-
The current status of PET scanning with respect to schizophrenia.Neuropsychopharmacology. 1992 Aug;7(1):41-54. Neuropsychopharmacology. 1992. PMID: 1388021 Review.
-
Utilization of radioligands in schizophrenia research.Clin Neurosci. 1995;3(2):112-21. Clin Neurosci. 1995. PMID: 7583617 Review.
Cited by
-
Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future.Curr Top Med Chem. 2016;16(29):3385-3403. doi: 10.2174/1568026616666160608084834. Curr Top Med Chem. 2016. PMID: 27291902 Free PMC article. Review.
-
Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers.Pharm Res. 2005 Sep;22(9):1432-7. doi: 10.1007/s11095-005-5882-3. Epub 2005 Aug 24. Pharm Res. 2005. PMID: 16132354
-
Enhancement of latent inhibition by two 5-HT2A receptor antagonists only when given at both pre-exposure and conditioning.Psychopharmacology (Berl). 2003 Sep;169(3-4):321-31. doi: 10.1007/s00213-002-1173-4. Epub 2002 Aug 9. Psychopharmacology (Berl). 2003. PMID: 14530903
-
Clinical utility of drug measurement and pharmacokinetics: therapeutic drug monitoring in psychiatry.Eur J Clin Pharmacol. 2008 Feb;64(2):159-66. doi: 10.1007/s00228-007-0430-1. Epub 2008 Jan 15. Eur J Clin Pharmacol. 2008. PMID: 18196227 Review.
-
Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data.CNS Drugs. 2011 Oct 1;25(10):829-45. doi: 10.2165/11591690-000000000-00000. CNS Drugs. 2011. PMID: 21936586 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical